Vici has completed first round of communication with FDA and is currently working on scaling up the manufacturing process in anticipation of entering the registration phase of the project.

ELKRIDGE, Md. (PRWEB)
December 27, 2019

Vici Health Sciences is announcing its successful completion of initial clinical studies for its 505(b)(2) product pipeline that offers patients and healthcare providers options in the treatment of chronic diseases that disproportionately affect geriatric patients. The products concepts were identified in collaboration with doctors and managed care professionals and developed at Vici’s R&D facility in Maryland. Vici has completed first round of communication with FDA and is currently working on scaling up the manufacturing process in anticipation of entering the registration phase of the project. Simultaneously Vici is in talks with its commercialization partners to ensure the doctors and patients have full access to these products that will significantly help improve patient outcomes.

About Vici Health Sciences LLC

Vici Health Sciences (Vici) is a U.S. based pharmaceutical research and development company. Vici is focused on specialty branded and generic pharmaceutical product development and commercialization. Vici’s goal is to improve clinical outcomes, enhance access, and reduce costs for patients and healthcare providers.